Safety and efficacy of Brinzolamide and Timolol eye drops to decrease intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension for whom single drug therapy provides insufficient for intraocular pressure reductio
- Conditions
- Health Condition 1: H00-H59- Diseases of the eye and adnexa
- Registration Number
- CTRI/2023/05/052720
- Lead Sponsor
- Sun Pharma Laboratories Limited (SPLL)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Patients of either gender aged >= 18 years who are willing to provide written informed consent
2.Patients diagnosed with Primary Openâ??angle glaucoma or Ocular hypertension
3.Patients who are on mono-therapy of either carbonic anhydrase inhibitors (CAIs) or Beta-blockers or any other IOP-lowering therapy and not adequately controlled
4.Women of childbearing potential must have a negative urine pregnancy test before study entry and agree to use highly effective methods of contraception to prevent pregnancy from study entry till at least two weeks after the last dose of the study medication
5.Male patients must have had a successful vasectomy or they and their female partners must meet the criteria above
1.Patients with a history of allergic hypersensitivity to oral or topical Carbonic Anhydrase Inhibitors, Beta -blockers, sulfonamide drugs, or any components of these medications
2.Patients with acute or chronic conjunctivitis
3.Patients with reactive airway disease including bronchial asthma or a history of bronchial asthma, or severe chronic obstructive pulmonary disease
4.Patients with known/history of sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block not controlled with pace-maker, overt cardiac failure, and cardiogenic shock
5.Patients with uncontrolled hypertension, dry eye syndrome, diabetic retinopathy, hyperchloraemic acidosis and uncontrolled diabetes
6.Patients with severe allergic rhinitis
7.Patients using intraocular corticosteroid implant
8.Patients using contact lenses within 1 week prior to enrolment
9.Patients using the following medications within two weeks prior to baseline of: 1) topical ophthalmic corticosteroid; 2) topical corticosteroid; 3) systemic corticosteroid, or 4) high dose salicylate therapy
10.Patients using intravitreal or subtenon injection of ophthalmic corticosteroid within 6 months prior to enrolment
11.Patients who are anticipated the need to initiate or modify medication that is known to affect IOP during the study period
12.Patients with severe renal impairment
13.Patients undergone intraocular surgery or laser surgery within the past 3 months
14.Patients currently using any systemic corticosteroid, or is having had therapy with any investigational agent within past 30 days
15.Patients with history of hematologic disorders other than mild anemia
16.Patients with history of non-compliance to medical regimens or those patients unwilling to comply with the study protocol
17.Patients with history of or currently having any of the severe/serious ocular condition or clinically significant medical conditions, such as cardiovascular, respiratory, renal, hepatic, endocrine, or gastrointestinal disease
18.Patients with history of or known case of HIV-AIDS, hepatitis B (Hep B), and hepatitis C (Hep C)
19.Participation in other studies involving investigational drugs or surgeries within the last 30 days or investigational biologics within the last 6 months prior to screening
20.Pregnant or lactating women and women of childbearing potential who are not using contraceptives
21.Investigator, study personnel, Sponsor representatives and their first degree relatives
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method